tiprankstipranks
Trending News
More News >
Abbvie (DE:4AB)
:4AB
Germany Market
Advertisement

AbbVie (4AB) Stock Forecast & Price Target

Compare
24 Followers
See the Price Targets and Ratings of:

4AB Analyst Ratings

Moderate Buy
19Ratings
Moderate Buy
14 Buy
5 Hold
0 Sell
Based on 19 analysts giving stock ratings to
AbbVie
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

4AB Stock 12 Month Forecast

Average Price Target

€189.93
▲(6.70% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is €189.93 with a high forecast of €218.97 and a low forecast of €145.98. The average price target represents a 6.70% change from the last price of €178.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"144":"€144","219":"€219","162.75":"€162.8","181.5":"€181.5","200.25":"€200.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":218.9660673,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€218.97</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":189.9337428474,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€189.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":145.9773782,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€145.98</span>\n  </div></div>","useHTML":true}}],"tickPositions":[144,162.75,181.5,200.25,219],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,168.4,172.2896974846154,176.17939496923077,180.06909245384617,183.95878993846154,187.84848742307693,191.7381849076923,195.6278823923077,199.51757987692307,203.40727736153846,207.29697484615383,211.18667233076923,215.07636981538462,{"y":218.9660673,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,168.4,170.0564417574923,171.7128835149846,173.3693252724769,175.02576702996924,176.68220878746155,178.33865054495385,179.99509230244615,181.65153405993846,183.30797581743076,184.96441757492306,186.6208593324154,188.2773010899077,{"y":189.9337428474,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,168.4,166.67518293846155,164.9503658769231,163.22554881538463,161.50073175384617,159.7759146923077,158.05109763076922,156.32628056923076,154.6014635076923,152.87664644615384,151.15182938461538,149.42701232307692,147.70219526153846,{"y":145.9773782,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":170.051,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.503,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.155,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.051,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":168.202,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.458,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.591,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":194.211,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.166,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.934,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.995,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.598,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":168.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€218.97Average Price Target€189.93Lowest Price Target€145.98
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Raymond James Analyst forecast on DE:4AB
Raymond James
Raymond James
€194.98€202.71
Buy
13.88%
Upside
Reiterated
08/25/25
Raymond James Sticks to Their Buy Rating for AbbVie (ABBV)
Bernstein
Hold
Reiterated
08/17/25
Analysts Conflicted on These Healthcare Names: Revolution Medicines (NASDAQ: RVMD), Astria Therapeutics (NASDAQ: ATXS) and AbbVie (NYSE: ABBV)
Cantor Fitzgerald Analyst forecast on DE:4AB
Cantor Fitzgerald
Cantor Fitzgerald
€180.38€184.67
Buy
3.75%
Upside
Reiterated
08/13/25
AbbVie (ABBV) Receives a Buy from Cantor Fitzgerald
Piper Sandler Analyst forecast on DE:4AB
Piper Sandler
Piper Sandler
€198.42
Buy
11.47%
Upside
Initiated
08/12/25
AbbVie: Strong Buy Rating Due to Minimal LOE Risks and Growth in Key Segments
Daiwa
€183.82
Buy
3.27%
Upside
Upgraded
08/07/25
AbbVie upgraded to Outperform from Neutral at DaiwaAbbVie upgraded to Outperform from Neutral at Daiwa
BMO Capital Analyst forecast on DE:4AB
BMO Capital
BMO Capital
€184.67
Buy
3.75%
Upside
Reiterated
08/04/25
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Axsome Therapeutics (NASDAQ: AXSM) and GE Healthcare Technologies Inc (NASDAQ: GEHC)
Leerink Partners Analyst forecast on DE:4AB
Leerink Partners
Leerink Partners
€180.38
Buy
1.34%
Upside
Reiterated
08/01/25
Analysts Offer Insights on Healthcare Companies: Agios Pharma (NASDAQ: AGIO), Madrigal Pharmaceuticals (NASDAQ: MDGL) and AbbVie (NYSE: ABBV)
Evercore ISI
€176.08€177.8
Buy
-0.11%
Downside
Reiterated
08/01/25
AbbVie price target raised to $207 from $205 at Evercore ISIAbbVie price target raised to $207 from $205 at Evercore ISI
Bank of America Securities Analyst forecast on DE:4AB
Bank of America Securities
Bank of America Securities
€188.97
Hold
6.16%
Upside
Reiterated
08/01/25
AbbVie: Balancing Strong Performance with Pricing Uncertainties and Valuation Concerns
Citi
Hold
Reiterated
08/01/25
Citi Reaffirms Their Hold Rating on AbbVie (ABBV)
Goldman Sachs Analyst forecast on DE:4AB
Goldman Sachs
Goldman Sachs
€169.21€186.39
Hold
4.71%
Upside
Reiterated
08/01/25
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Castle Biosciences (NASDAQ: CSTL) and Regeneron (NASDAQ: REGN)
Guggenheim Analyst forecast on DE:4AB
Guggenheim
Guggenheim
€185.53€194.98
Buy
9.54%
Upside
Reiterated
07/31/25
Guggenheim Remains a Buy on AbbVie (ABBV)
TD Cowen Analyst forecast on DE:4AB
TD Cowen
TD Cowen
€214.74
Buy
20.64%
Upside
Reiterated
07/31/25
TD Cowen Sticks to Its Buy Rating for AbbVie (ABBV)
Wells Fargo Analyst forecast on DE:4AB
Wells Fargo
Wells Fargo
€180.38€206.15
Buy
15.81%
Upside
Reiterated
07/31/25
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Bio-Rad Laboratories (NYSE: BIO)
Morgan Stanley Analyst forecast on DE:4AB
Morgan Stanley
Morgan Stanley
€214.74€219.03
Buy
23.05%
Upside
Reiterated
07/31/25
AbbVie Receives Buy Rating from Terence Flynn Due to Strong Financial Performance and Growth Potential
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Raymond James Analyst forecast on DE:4AB
Raymond James
Raymond James
€194.98€202.71
Buy
13.88%
Upside
Reiterated
08/25/25
Raymond James Sticks to Their Buy Rating for AbbVie (ABBV)
Bernstein
Hold
Reiterated
08/17/25
Analysts Conflicted on These Healthcare Names: Revolution Medicines (NASDAQ: RVMD), Astria Therapeutics (NASDAQ: ATXS) and AbbVie (NYSE: ABBV)
Cantor Fitzgerald Analyst forecast on DE:4AB
Cantor Fitzgerald
Cantor Fitzgerald
€180.38€184.67
Buy
3.75%
Upside
Reiterated
08/13/25
AbbVie (ABBV) Receives a Buy from Cantor Fitzgerald
Piper Sandler Analyst forecast on DE:4AB
Piper Sandler
Piper Sandler
€198.42
Buy
11.47%
Upside
Initiated
08/12/25
AbbVie: Strong Buy Rating Due to Minimal LOE Risks and Growth in Key Segments
Daiwa
€183.82
Buy
3.27%
Upside
Upgraded
08/07/25
AbbVie upgraded to Outperform from Neutral at DaiwaAbbVie upgraded to Outperform from Neutral at Daiwa
BMO Capital Analyst forecast on DE:4AB
BMO Capital
BMO Capital
€184.67
Buy
3.75%
Upside
Reiterated
08/04/25
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Axsome Therapeutics (NASDAQ: AXSM) and GE Healthcare Technologies Inc (NASDAQ: GEHC)
Leerink Partners Analyst forecast on DE:4AB
Leerink Partners
Leerink Partners
€180.38
Buy
1.34%
Upside
Reiterated
08/01/25
Analysts Offer Insights on Healthcare Companies: Agios Pharma (NASDAQ: AGIO), Madrigal Pharmaceuticals (NASDAQ: MDGL) and AbbVie (NYSE: ABBV)
Evercore ISI
€176.08€177.8
Buy
-0.11%
Downside
Reiterated
08/01/25
AbbVie price target raised to $207 from $205 at Evercore ISIAbbVie price target raised to $207 from $205 at Evercore ISI
Bank of America Securities Analyst forecast on DE:4AB
Bank of America Securities
Bank of America Securities
€188.97
Hold
6.16%
Upside
Reiterated
08/01/25
AbbVie: Balancing Strong Performance with Pricing Uncertainties and Valuation Concerns
Citi
Hold
Reiterated
08/01/25
Citi Reaffirms Their Hold Rating on AbbVie (ABBV)
Goldman Sachs Analyst forecast on DE:4AB
Goldman Sachs
Goldman Sachs
€169.21€186.39
Hold
4.71%
Upside
Reiterated
08/01/25
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Castle Biosciences (NASDAQ: CSTL) and Regeneron (NASDAQ: REGN)
Guggenheim Analyst forecast on DE:4AB
Guggenheim
Guggenheim
€185.53€194.98
Buy
9.54%
Upside
Reiterated
07/31/25
Guggenheim Remains a Buy on AbbVie (ABBV)
TD Cowen Analyst forecast on DE:4AB
TD Cowen
TD Cowen
€214.74
Buy
20.64%
Upside
Reiterated
07/31/25
TD Cowen Sticks to Its Buy Rating for AbbVie (ABBV)
Wells Fargo Analyst forecast on DE:4AB
Wells Fargo
Wells Fargo
€180.38€206.15
Buy
15.81%
Upside
Reiterated
07/31/25
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Bio-Rad Laboratories (NYSE: BIO)
Morgan Stanley Analyst forecast on DE:4AB
Morgan Stanley
Morgan Stanley
€214.74€219.03
Buy
23.05%
Upside
Reiterated
07/31/25
AbbVie Receives Buy Rating from Terence Flynn Due to Strong Financial Performance and Growth Potential
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbbVie

1 Month
xxx
Success Rate
18/28 ratings generated profit
64%
Average Return
+3.47%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 64.29% of your transactions generating a profit, with an average return of +3.47% per trade.
3 Months
xxx
Success Rate
19/25 ratings generated profit
76%
Average Return
+7.72%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 76.00% of your transactions generating a profit, with an average return of +7.72% per trade.
1 Year
Mohit BansalWells Fargo
Success Rate
22/22 ratings generated profit
100%
Average Return
+18.60%
reiterated a buy rating 28 days ago
Copying Mohit Bansal's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +18.60% per trade.
2 Years
xxx
Success Rate
28/28 ratings generated profit
100%
Average Return
+31.34%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +31.34% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4AB Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
0
0
0
0
0
Buy
30
24
27
25
33
Hold
12
17
21
24
20
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
42
41
48
49
53
In the current month, 4AB has received 33 Buy Ratings, 20 Hold Ratings, and 0 Sell Ratings. 4AB average Analyst price target in the past 3 months is 189.93.
Each month's total comprises the sum of three months' worth of ratings.

4AB Financial Forecast

4AB Earnings Forecast

Next quarter’s earnings estimate for 4AB is €2.79 with a range of €2.66 to €2.90. The previous quarter’s EPS was €2.54. 4AB beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 0.00% of the time in the same period. In the last calendar year 4AB has Outperformed its overall industry.
Next quarter’s earnings estimate for 4AB is €2.79 with a range of €2.66 to €2.90. The previous quarter’s EPS was €2.54. 4AB beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 0.00% of the time in the same period. In the last calendar year 4AB has Outperformed its overall industry.

4AB Sales Forecast

Next quarter’s sales forecast for 4AB is €13.30B with a range of €12.91B to €13.66B. The previous quarter’s sales results were €13.19B. 4AB beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 0.00% of the time in the same period. In the last calendar year 4AB has Outperformed its overall industry.
Next quarter’s sales forecast for 4AB is €13.30B with a range of €12.91B to €13.66B. The previous quarter’s sales results were €13.19B. 4AB beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 0.00% of the time in the same period. In the last calendar year 4AB has Outperformed its overall industry.

4AB Stock Forecast FAQ

What is DE:4AB’s average 12-month price target, according to analysts?
Based on analyst ratings, Abbvie’s 12-month average price target is 189.93.
    What is DE:4AB’s upside potential, based on the analysts’ average price target?
    Abbvie has 6.70% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Abbvie a Buy, Sell or Hold?
          Abbvie has a consensus rating of Moderate Buy, which is based on 14 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Abbvie’s share price target?
            The average share price target for Abbvie is 189.93. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €218.97 ,and the lowest forecast is €145.98. The average share price target represents 6.70% Increase from the current price of €178.
              What do analysts say about Abbvie?
              Abbvie’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of Abbvie?
                To buy shares of DE:4AB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis